Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer forecasts 2019 revenue below Wall Street targets

Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.

Read More »

Biogen beats Q4 2018 estimates on sales of multiple sclerosis drugs

Biogen Inc. beat analysts’ estimates for fourth-quarter profit and revenue, buoyed by higher sales of the company’s top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

Read More »

AbbVie’s 2018: Revenues Up, Earnings Down

AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for full-year 2018, however, hitting $32.75 billion compared to $28.2 billion in 2017.

Read More »

Bristol-Myers Squibb 2018 Full-Year Financials: “Superior Commercial Performance”

Bristol-Myers Squibb reported that fourth-quarter 2018 revenue was up 10 percent and full-year revenue increased 9 percent.

Read More »

Bristol-Myers pulls U.S. application for combo lung cancer treatment

Bristol-Myers Squibb withdrew the U.S. approval application for a combo of the cancer immunotherapy drugs Opdivo and Yervoy.

Read More »

Abbott’s Q4 2018 Revenue Misses Estimate, Forecasts Lackluster Q1 2019 Profit

Abbott’s fourth-quarter 2018 revenue fell short of Wall Street expectations due to lower sales of generic drugs in emerging markets as well as a strong dollar, and the healthcare company forecast first-quarter 2019 earnings below analysts’ estimates.

Read More »

J&J fourth-quarter 2018 sales beat expectations

Johnson & Johnson reported better-than-expected fourth-quarter revenue, helped by strong demand for the company’s drugs to treat cancer and psoriasis.

Read More »

Selecta Biosciences Restructures, Cuts 36% of Staff

Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.

Read More »

AstraZeneca Q3 2018 drug sales turn corner

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in third-quarter 2018 and the drugmaker anticipates years of sustained improvement and rising profit margins.

Read More »

India’s Dr. Reddy’s Q2 profit surges nearly 70 percent

Indian drugmaker Dr. Reddy’s Laboratories posted a 69.7 percent jump in fiscal second-quarter 2018 profit, helped by new product launches.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom